

**Cadila Healthcare Ltd. - Consolidated
Break-up of Gross Sales**

Rs. Mio.

Particulars	Q2 09-10	Q2 08-09	% Gr y-y	YTD 09-10	YTD 08-09	% Gr y-y
Domestic	5,012	4,504	11.3%	9,770	8,717	12.1%
Formulations	3,935	3,579	9.9%	7,654	6,863	11.5%
Branded Formulations	3,695	3,356	10.1%	7,229	6,492	11.4%
Generic Formulations	240	223	7.6%	425	371	14.6%
API	87	123	-29.3%	169	262	-35.5%
Consumer & Others	990	802	23.4%	1,947	1,592	22.3%
Consumer Products	649	472	37.4%	1,290	972	32.7%
Animal Health & Others	341	330	3.4%	657	620	5.9%
Exports	4,238	3,082	37.5%	8,376	5,847	43.3%
Formulations	3,199	2,186	46.3%	6,526	4,192	55.7%
North America (US)	1,604	798	101.0%	3,082	1,617	90.6%
Europe	528	464	13.8%	1,166	922	26.5%
Latin America	461	402	14.6%	826	825	0.1%
Japan	72	41	75.6%	156	64	142.2%
Emerging Markets	332	481	-31.1% ##	858	763	12.4%
Zydus Hospira (50%)	203	0		437	0	
API	1,039	896	16.0%	1,850	1,655	11.8%
Zydus Nycomed (50%)	208	320	-34.9%	503	596	-15.7%
Others	831	576	44.2%	1,347	1,059	27.2%
Total	9,250	7,586	21.9%	18,146	14,564	24.6%

Emerging Markets include Simayla, South Africa. In previous year i.e. in Q2 08-09, Simayla numbers included sales of six months from Apr-Sep 08, since the company was acquired in July-09. Hence, the numbers for Q2 09-10 are not comparable.

For better comparison, please look at YTD (Apr-Sep) numbers for Emerging Markets.

Cadila Healthcare Ltd. - Consolidated
Other Details pertaining to Q2 and H1 09-10

Rs. Mio.

R&D Expenses	Q2 09-10	Q2 08-09	% Gr y-y	YTD 09-10	YTD 08-09	% Gr y-y
R&D Revenue Expenses	474	328	44.5%	943	718	31.3%
R&D Capex	61			181		

Other Incomes	Q2 09-10	Q2 08-09	% Gr y-y	YTD 09-10	YTD 08-09	% Gr y-y
A. Operating Income						
a. Export Incentive	23	21	9.5%	48	40	20.0%
b. Exchange Rate Fluctuation (Net)		-156		0	0	
c. Processing Income	132	96	37.5%	236	189	24.9%
d. Royalty Income	72			135		
e. Others	105	70	50.0%	145	85	70.6%
Total Operating Income	332	31	971.0%	564	314	79.6%
B. Other Income						
a. Dividend	1			1		
b. Interest Income	31	27	13.3%	70	40	73.3%
c. Rent received	2			5	3	66.7%
d. Profit on sale of assets	7			7		
Total Other Income	41	27	49.9%	83	43	91.2%

Exceptional Items	Q2 09-10	Q2 08-09	% Gr y-y	YTD 09-10	YTD 08-09	% Gr y-y
Compensation under Voluntary Retirement Scheme (in Brazil and Liva Healthcare)	4	18	-77.8%	13	18	-27.8%
Expenses incurred on Composite Scheme of Arrangement (in Zydus Wellness Ltd.)	22			22		
Total	26	18	44.4%	35	18	94.4%

Consolidated Capex for Apr-Sep 09 (Excl. Goodwill)	Rs. 1435 Mio.
---	----------------------